Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Category

Cardiovascular and metabolic diseases

153 articles in this topic.

Articles in this category

CHMP November 2026 Recommends Seven New Medicines for Approval

11/16/2026

CHMP November 2026 Recommends Seven New Medicines for Approval

EMA's CHMP recommended seven new medicines and 11 indication extensions at its 9 to 12 November 2026 meeting, and confirmed two refusals after re-examination.
Read Article →
Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet

11/16/2026

Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet

The CHMP recommended granting a marketing authorisation for AstraZeneca's Baxfendy (baxdrostat) for insufficiently controlled hypertension. The European Commission makes the final decision. #SyenzaNews #MarketAccess
Read Article →
Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo

11/10/2026

Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo

The FDA approved Sunharbo (asundexian), the first factor XIa inhibitor for stroke prevention, for adults after a recent ischemic stroke or high-risk TIA. #SyenzaNews #MarketAccess
Read Article →
Mayo Clinic’s TV question for the home blood pressure monitor

11/3/2026

Mayo Clinic’s TV question for the home blood pressure monitor

A Mayo Clinic cardiologist's TV-set question makes the case for a home blood pressure monitor, with a caution on device reliability and home data in the chart.
Read Article →
Lancet Authors Make the Case for an EU Medical Device Agency

10/30/2026

Lancet Authors Make the Case for an EU Medical Device Agency

Four authors writing in The Lancet Regional Health - Europe say the Commission's MDR and IVDR simplification proposal keeps the core flaw: notified bodies still decide, one by one, whether innovative devices reach the market. They argue for an EU medical device agency with binding powers over strategy, guidance and advice. #SyenzaNews #MedTech #MedicalDevices #MarketAccess
Read Article →
FDA Approves Autus Size-Adjustable Valve That Grows With Children

10/2/2026

FDA Approves Autus Size-Adjustable Valve That Grows With Children

FDA approval of the Autus Size-Adjustable Valve gives children with congenital pulmonary valve disease a pulmonary valve that can be widened as they grow, from 13 millimeters to 22 millimeters. The evidence base is 62 patients and six months of follow-up. #SyenzaNews #medicaldevices #pediatrics #MarketAccess
Read Article →
Novo Nordisk Halts Ziltivekimab Heart Failure Trials

9/8/2026

Novo Nordisk Halts Ziltivekimab Heart Failure Trials

Novo Nordisk has stopped the two remaining ziltivekimab heart failure trials after a futility review, leaving ARTEMIS as the last anti-inflammatory cardiovascular outcomes bet. #SyenzaNews #MarketAccess #Cardiology #HTA
Read Article →
Specialist Payment Models: Triple the Cardiac Testing, No Difference in Outcomes

8/27/2026

Specialist Payment Models: Triple the Cardiac Testing, No Difference in Outcomes

In Alberta, patients of fee-for-service heart specialists receive roughly three times the cardiac testing, with no measurable difference in outcomes. #HealthEconomics #PhysicianPayment #SyenzaNews
Read Article →
SAGA Trial Supports Statin Discontinuation in Elderly

8/13/2026

SAGA Trial Supports Statin Discontinuation in Elderly

💊 Is it safe to stop statins in elderly patients for primary prevention? A recent trial shows that deprescribing statins in older adults without established cardiovascular disease does not increase the risk of adverse outcomes, supporting more individualized prescribing decisions. Discover the full trial results and implications for clinical practice. #SyenzaNews #clinicaltrials #pharmaceuticals #costeffectiveness #healthcarepolicy
Read Article →
Brazil pharmaceutical supply chain vulnerabilities exposed by pandemic disruptions

7/20/2026

Brazil pharmaceutical supply chain vulnerabilities exposed by pandemic disruptions

🔍 How did the pandemic expose critical weaknesses in Brazil’s pharmaceutical supply chain? From raw-material dependencies to distribution bottlenecks, COVID-19 disruptions laid bare vulnerabilities that continue to threaten medicine availability and market access across the region. Read the full analysis to see what these lessons mean for building more resilient supply systems. #SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #healthcarepolicy
Read Article →
NICE Finerenone HFpEF Approval Advances HFpEF Therapy Options

7/16/2026

NICE Finerenone HFpEF Approval Advances HFpEF Therapy Options

How is NICE expanding treatment options for HFpEF patients? The UK’s National Institute for Health and Care Excellence has approved finerenone, giving clinicians a new evidence-based therapy to improve outcomes in heart failure with preserved ejection fraction. This milestone broadens the therapeutic landscape and reinforces the value of targeted drug development. Read the full analysis. #SyenzaNews #pharmaceuticals #HealthcareInnovation #innovation #MarketAccess
Read Article →
Early TAVR Surveillance Cost-Effectiveness Analysis Demonstrates Economic Dominance

7/9/2026

Early TAVR Surveillance Cost-Effectiveness Analysis Demonstrates Economic Dominance

Could earlier surveillance after TAVR unlock better outcomes at lower cost? 💡📈 A new analysis finds that proactive early‑post‑TAVR surveillance has the potential to be cost‑effective — and in many modeled scenarios, economically dominant — by improving patient outcomes while reducing downstream costs. The piece highlights key assumptions, sensitivity analyses, and implications for clinicians, payers, and policymakers. Read the full article to understand the evidence and what it means for adopting early surveillance strategies. #SyenzaNews #HealthEconomics #HealthTechnology #costeffectiveness #MarketAccess
Read Article →

Related topics